Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X about a paper she co-authored with colleagues published in JCO Oncology Advances:
“Prior anti-PD1/pdl1 does not compromise responses to nivolumab plus ipilumumab. Results from DART (NCI/SWOG): largest immunotherapy rare cancer trial.”
Title: Outcomes of Patients With Rare Cancers Treated With Combination Immune Checkpoint Inhibitors With and Without Previous Anti–PD-1/L1 Exposure: National Cancer Institute/SWOG S1609
Authors: Megan Othus, Sandip P. Patel, Young Kwan Chae, Eliana Dietrich, Manmeet S. Ahluwalia, Razelle Kurzrock
You can read the full article in JCO Oncology Advances.
More posts featuring Razelle Kurzrock.